Matthew Fowler | Authors


Daratumumab/CyBorD Followed By Maintenance Leads to Deep Responses in Multiple Myeloma

June 21, 2021

Results from the LYRA trial showed that the combination of daratumumab with cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses in patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status.